8-K: BiomX Faces Delisting Threat After Failing to Meet NYSE American Equity Requirements

BiomX Inc. has received a notice from the NYSE American for failing to meet continued listing standards due to a stockholders equity deficiency, requiring the company to submit a compliance plan by June 22, 2024.

Summary

• BiomX Inc. received a notification from the NYSE American on May 23, 2024, stating the company is not compliant with continued listing standards.
• The company's stockholders equity is below the required thresholds of $2 million, $4 million, and $6 million, as it reported a total stockholders capital deficiency of $9,544,000 as of March 31, 2024.
• BiomX has until June 22, 2024, to submit a plan to regain compliance by November 23, 2025.
• The plan must include specific milestones, quarterly financial projections, and details of strategic initiatives.
• A stockholder meeting is expected in July 2024 to approve the conversion of Series X Non-Voting Convertible Preferred Stock into Common Stock, which could reclassify at least $32.4 million to stockholders equity.
• If the plan is not submitted, not accepted, or if the company fails to meet the standards by November 23, 2025, BiomX could be delisted from the NYSE American.
• The company's stock will continue to trade on the NYSE American under the symbol PHGE, but with an added designation of .BC to indicate its below compliance status.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting notice and the company's financial struggles. While there are potential solutions, the risk of delisting is significant.

Positives

• The company is preparing a plan to regain compliance with the NYSE American listing standards.
• A potential conversion of preferred stock to common stock could add at least $32.4 million to stockholders equity.
• The company's stock will continue to trade on the NYSE American during the compliance period.

Negatives

• BiomX is currently not in compliance with NYSE American listing standards due to a significant stockholders equity deficiency.
• The company faces the risk of delisting if it fails to submit an acceptable compliance plan or meet the standards by November 23, 2025.
• Delisting could negatively impact the company's stock price, liquidity, and ability to raise capital.

Risks

• There is no guarantee that the company will be able to submit an acceptable compliance plan to the NYSE American.
• The company may not be able to regain compliance with the listing standards by the required deadline of November 23, 2025.
• Delisting could reduce the liquidity and market price of the company's stock and limit its ability to raise capital.
• The company's ability to provide equity incentives to employees could be impaired if delisted.

Future Outlook

BiomX is focused on submitting a compliance plan to the NYSE American and regaining compliance with listing standards by November 23, 2025. The company is also seeking stockholder approval for a preferred stock conversion that could improve its equity position.

Management Comments

• The Company is committed to achieving compliance with the NYSE Americans requirements.
• There can be no assurance that the Company will be able to achieve compliance with the NYSE Americans continued listing standards within the required timeframe.

Industry Context

This announcement highlights the challenges faced by biotech companies in maintaining financial stability and meeting listing requirements, particularly after acquisitions and during periods of losses. It is not uncommon for companies in this sector to face delisting risks if they do not meet minimum equity requirements.

Comparison to Industry Standards

• Many biotech companies, especially those in early stages of development, struggle to maintain positive stockholders equity due to high research and development costs and limited revenue.
• Companies like Cassava Sciences (SAVA) and Ocugen (OCGN) have also faced scrutiny regarding their financial positions and compliance with listing standards.
• The requirement to maintain a minimum level of stockholders equity is a common hurdle for companies listed on exchanges like NYSE American, and failure to meet these standards can lead to delisting.

Management Changes

Stakeholder Impact

• Shareholders face the risk of a decline in stock value and liquidity if the company is delisted.
• Employees may be affected by the company's financial instability and potential delisting.
• The company's ability to raise capital could be negatively impacted, affecting future growth and operations.

Next Steps

• BiomX will submit a compliance plan to the NYSE American by June 22, 2024.
• The company will seek stockholder approval for the conversion of Series X Non-Voting Convertible Preferred Stock into Common Stock at a meeting expected in July 2024.
• BiomX will work to regain compliance with NYSE American listing standards by November 23, 2025.

Key Dates

Keywords

delisting, NYSE American, stockholders equity, compliance plan, listing standards, BiomX, PHGE, capital deficiency